Physician profile
Todd B Lapoint
NPI 1588770630
$2,972.21
in general payments reported to CMS, 2019-2025
26 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $597 · 2021: $339 · 2022: $467 · 2023: $371 · 2024: $494 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $500.23 | 2020-2024 | Hydrus Microstent, Total30, Precision 1 |
| Allergan, INC. | $318.88 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $295.25 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $286.58 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $220.00 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Sun Pharmaceutical Industries INC. | $157.25 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.02 | 2019-2021 | |
| Oyster Point Pharma, INC. | $136.67 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $133.34 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $114.47 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $92.20 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $91.03 | 2023 | Acthar |
| Harrow Eye, LLC | $81.41 | 2023-2024 | Iheezo |
| Biotissue Holdings INC. | $54.74 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $44.37 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $41.53 | 2023-2025 | Iyuzeh |
| Rxsight INC | $34.58 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $33.23 | 2019-2024 | Tecnis Iol |
| Coopervision INC. | $29.75 | 2023-2024 | Biofinity Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $29.67 | 2023 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $27.97 | 2022 | |
| Astellas Pharma US INC | $25.30 | 2023 | |
| Sight Sciences, INC. | $24.94 | 2023 | Tearcare System |
| Horizon Therapeutics Plc | $16.57 | 2021 | |
| Shire North American Group INC | $15.29 | 2019 | |
| Genentech USA, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lapoint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.